Anti CD38 monoclonal antibodies for multiple myeloma treatment

被引：35

作者：

Gozzetti, Alessandro ^{[1
]}

Ciofini, Sara ^{[1
]}

Simoncelli, Martina ^{[1
]}

Santoni, Adele ^{[1
]}

Pacelli, Paola ^{[1
]}

Raspadori, Donatella ^{[1
]}

Bocchia, Monica ^{[1
]}

机构：

[1] Univ Siena, Hematol, Dept Med Sci Surg & Neurosci, Siena, Italy

来源：

HUMAN VACCINES & IMMUNOTHERAPEUTICS | 2022年 / 18卷 / 05期

关键词：

multiple myeloma; monoclonal antibodies; daratumumab; isatuximab; CD38; minimal residual disease; CYCLIC ADP-RIBOSE; DARATUMUMAB PLUS POMALIDOMIDE; OPEN-LABEL; OUTER SURFACE; CELL-DEATH; DEXAMETHASONE; EXPRESSION; MULTICENTER; MONOTHERAPY; HYDROLYSIS;

D O I：

10.1080/21645515.2022.2052658

中图分类号：

Q81 [生物工程学（生物技术）]; Q93 [微生物学];

学科分类号：

071005 ; 0836 ; 090102 ; 100705 ;

摘要：

CD38 is a transmembrane glycoprotein with ectoenzymatic activity and is highly and uniformly expressed on multiple myeloma (MM) cells. CD38 is expressed also at relatively low levels on normal lymphoid and myeloid cells, and in some tissues of non-hematopoietic origin. The specificity of this target has increased interest in new drugs and triggered the development of the CD38 monoclonal antibodies Daratumumab (fully human) and Isatuximab (chimeric). CD38 antibodies have pleiotropic mechanisms of action including Fc-dependent immune effector mechanisms, direct apoptotic activity, and immunomodulatory effects by the elimination of CD38+ immune-suppressor cells. Monoclonal antibody-based therapy has revolutionized MM therapy in the latest years increasing depth of response. This product review will focus on anti-CD38 monoclonal antibodies Daratumumab and Isatuximab efficacy, safety, pharmacokinetic and pharmacodynamic data from clinical trials.

引用

页数：9

共 70 条

[1] Ninety-minute daratumumab infusion is safe in multiple myeloma [J].

Barr, Hallie ;

Dempsey, Jessica ;

Waller, Allyson ;

Huang, Ying ;

Williams, Nita ;

Sharma, Nidhi ;

Benson, Don M. ;

Rosko, Ashley E. ;

Efebera, Yvonne A. ;

Hofmeister, Craig C. .

LEUKEMIA, 2018, 32 (11) :2495-2497

[2] MOR202, a Human Anti-CD38 Monoclonal Antibody, Mediates Potent Tumoricidal Activity In Vivo and Shows Synergistic Efficacy in Combination with Different Antineoplastic Compounds [J].

Boxhammer, Rainer ;

Weirather, Johannes ;

Steidl, Stefan ;

Endell, Jan .

BLOOD, 2015, 126 (23)

[3] Lenalidomide enhances MOR202-dependent macrophage -mediated effector functions via the vitamin D pathway [J].

Busch, Leonhard ;

Mougiakakos, Dimitrios ;

Buettner-Herold, Maike ;

Mueller, Miriam J. ;

Volmer, Dietrich A. ;

Bach, Christian ;

Fabri, Mario ;

Bittenbring, Joerg T. ;

Neumann, Frank ;

Boxhammer, Rainer ;

Nolting, Jens ;

Bisht, Savita ;

Boettcher, Martin ;

Jitschin, Simon ;

Hoffmann, Markus H. ;

Balzer, Heidi ;

Beier, Fabian ;

Gezer, Deniz ;

Dudziak, Diana ;

Gelse, Kolja ;

Hennig, Friedrich F. ;

Pallasch, Christian P. ;

Spriewald, Bernd ;

Mackensen, Andreas ;

Bruns, Heiko .

LEUKEMIA, 2018, 32 (11) :2445-2458

[4] IgM myeloma: A multicenter retrospective study of 134 patients [J].

Castillo, Jorge J. ;

Jurczyszyn, Artur ;

Brozova, Lucie ;

Crusoe, Edvan ;

Czepiel, Jacek ;

Davila, Julio ;

Dispenzieri, Angela ;

Eveillard, Marion ;

Fiala, Mark A. ;

Ghobrial, Irene M. ;

Gozzetti, Alessandro ;

Gustine, Joshua N. ;

Hajek, Roman ;

Hungria, Vania ;

Jarkovsky, Jiri ;

Jayabalan, David ;

Laubach, Jacob P. ;

Lewicka, Barbara ;

Maisnar, Vladimir ;

Manasanch, Elisabet E. ;

Moreau, Philippe ;

Morgan, Elizabeth A. ;

Nahi, Hareth ;

Niesvizky, Ruben ;

Paba-Prada, Claudia ;

Pika, Tomas ;

Pour, Ludek ;

Reagan, John L. ;

Richardson, Paul G. ;

Shah, Jatin ;

Spicka, Ivan ;

Vij, Ravi ;

Waszczuk-Gajda, Anna ;

Gertz, Morie A. .

AMERICAN JOURNAL OF HEMATOLOGY, 2017, 92 (08) :746-751

[5] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma [J].

Chari, Ajai ;

Suvannasankha, Attaya ;

Fay, Joseph W. ;

Arnulf, Bertrand ;

Kaufman, Jonathan L. ;

Ifthikharuddin, Jainulabdeen J. ;

Weiss, Brendan M. ;

Krishnan, Amrita ;

Lentzsch, Suzanne ;

Comenzo, Raymond ;

Wang, Jianping ;

Nottage, Kerri ;

Chiu, Christopher ;

Khokhar, Nushmia Z. ;

Ahmadi, Tahamtan ;

Lonial, Sagar .

BLOOD, 2017, 130 (08) :974-981

[6] CD38 is the major enzyme responsible for synthesis of nicotinic acid-adenine dinucleotide phosphate in mammalian tissues [J].

Chini, EN ;

Chini, CCS ;

Kato, I ;

Takasawa, S ;

Okamoto, H .

BIOCHEMICAL JOURNAL, 2002, 362 :125-130

[7] Homing of antibody secreting cells [J].

Cyster, JG .

IMMUNOLOGICAL REVIEWS, 2003, 194 (01) :48-60

[8] Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia [J].

Damle, RN ;

Wasil, T ;

Fais, F ;

Ghiotto, F ;

Valetto, A ;

Allen, SL ;

Buchbinder, A ;

Budman, D ;

Dittmar, K ;

Kolitz, J ;

Lichtman, SM ;

Schulman, P ;

Vinciguerra, VP ;

Rai, KR ;

Ferrarini, M ;

Chiorazzi, N .

BLOOD, 1999, 94 (06) :1840-1847

[9] Human CD38: a (r)evolutionary story of enzymes and receptors [J].

Deaglio, S ;

Mehta, K ;

Malavasi, F .

LEUKEMIA RESEARCH, 2001, 25 (01) :1-12

[10] Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma [J].

Dimopoulos, M. A. ;

Oriol, A. ;

Nahi, H. ;

San-Miguel, J. ;

Bahlis, N. J. ;

Usmani, S. Z. ;

Rabin, N. ;

Orlowski, R. Z. ;

Komarnicki, M. ;

Suzuki, K. ;

Plesner, T. ;

Yoon, S. -S. ;

Ben Yehuda, D. ;

Richardson, P. G. ;

Goldschmidt, H. ;

Reece, D. ;

Lisby, S. ;

Khokhar, N. Z. ;

O'Rourke, L. ;

Chiu, C. ;

Qin, X. ;

Guckert, M. ;

Ahmadi, T. ;

Moreau, P. .

NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (14) :1319-1331

← 1 2 3 4 5 6 7 →